NCI-2023-03139

A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors

This study is investigating the use of a new medicine called IDE161 in participants with advanced solid tumors. The main purpose of the study is to evaluate the safety and efficacy of IDE161 in this patient population. The researchers aim to assess how well IDE161 works in shrinking tumors and whether it has manageable side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05787587

Clinical Trial Site: Columbia

To see all available clinical trials click here.